Login / Signup
Safety in numbers: risankizumab for moderate-to-severe psoriasis.
Sara Mirali
K Fabusiwa
Eleni Linos
Published in:
The British journal of dermatology (2022)
Keyphrases
</>
high intensity
early onset
drug induced